Torrent Pharmaceuticals announced strong Q2 FY26 results, with revenue up 14% YoY to ₹3,302 crores. Operating EBITDA increased by 15% YoY to ₹1,083 crores, and net profit after tax rose by 30% YoY to ₹591 crores. The company’s performance was driven by strong branded business results. India revenues increased by 12%. The company’s operating EBITDA margin was 32.8%.
Financial Highlights
Torrent Pharmaceuticals announced its financial results for Q2 FY26, showcasing significant growth in revenue and profitability:
- Revenue: Increased by 14% year-over-year to ₹3,302 crores.
- Operating EBITDA: Grew by 15% year-over-year to ₹1,083 crores.
- Operating EBITDA Margin: Reached 32.8%.
- Net Profit After Tax: Surged by 30% year-over-year to ₹591 crores.
Segment Performance
The company experienced notable performance across key geographic segments:
- India: Revenues increased by 12% to ₹1,820 crores.
- Brazil: Revenues increased by 21% to ₹318 crores.
- United States: Revenues increased by 26% to ₹337 crores.
- Germany: Revenues increased by 5% to ₹303 crores.
Strategic Developments
Torrent Pharma’s strong performance is underscored by strategic moves aimed at expanding its market presence. They have entered into a definitive agreement to acquire a controlling stake in JB Chemicals & Pharmaceuticals Ltd, which is still subject to statutory approvals. The exceptional items for this quarter pertain to regulatory and statutory fees related to this proposed transaction.
Key Ratios & Metrics
Several key financial ratios reflect a positive outlook:
- Debt-Equity Ratio: 0.31 times.
- Debt Service Coverage Ratio: 2.98 times.
- Interest Service Coverage Ratio: 17.15 times.
- Net Profit Margin: 17.9%.
Source: BSE
